Prescription medicine
Enoxaparin Brand names: Lovenox; first approved as Lovenox (Preservative Free)
Enoxaparin (Lovenox) is a prescription medicine with an FDA approval on record since 1993. FDA's NDC Directory lists it from 16 generic labelers, and pharmacies paid $6.45 per mL (Enoxaparin 100 mg/mL syringe) in the October 7, 2026 NADAC survey.
- Generic listed
- Boxed warning
Check it at the source: the enoxaparin FDA label on DailyMed (effective May 28, 2026, Sanofi-Aventis U.S. LLC); the NDA 20164 record on Drugs@FDA; every enoxaparin label on DailyMed.
Highlights of the record
FDA label of May 28, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
SPINAL/EPIDURAL HEMATOMAS.
Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include: Use of indwelling epidural catheters Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, and other anticoagulants A history of traumatic or repeated epidural or spinal punctures A history of spinal deformity or spinal surgery Optimal timing between the administration of Lovenox and neuraxial procedures is not known Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary. Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis [see Warnings and Precautions (5.1) and Drug Interactions (7) ]. WARNING: SPINAL/EPIDURAL HEMATOMAS See full prescribing information for complete boxed warning. […]
Used for
From the label: indications and usageLovenox is a low molecular weight heparin (LMWH) indicated for: Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness ( 1.1 ) Inpatient treatment of acute DVT with or without pulmonary embolism ( 1.2 ) Outpatient treatment of acute DVT without pulmonary embolism ( 1.2 ) Prophylaxis o
Forms and strengths
- 30 mg/.3ml
- 40 mg/.4ml
- 60 mg/.6ml
- 80 mg/.8ml
- 100 mg/ml
- 120 mg/.8ml
- 150 mg/ml
- 300 mg/3ml
Injection; injection (solution).
On the market
- Earliest approval on file
- March 29, 1993 Lovenox (Preservative Free), Sanofi Aventis Us; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 11 first July 23, 2010; 11 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 17 of which 16 under generic applications, 2 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $6.45 per mL Enoxaparin 100 mg/mL syringe
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 6 since 2017 3 Class I among all firms' recalls; latest August 5, 2025
- FAERS reports
- 57,205 through July 30, 2026
What is enoxaparin used for?
From the label: indications and usageLovenox is a low molecular weight heparin (LMWH) indicated for: Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness ( 1.1 ) Inpatient treatment of acute DVT with or without pulmonary embolism ( 1.2 ) Outpatient treatment of acute DVT without pulmonary embolism ( 1.2 ) Prophylaxis of ischemic complications of unstable angina and non–Q-wave myocardial infarction (MI) ( 1.3 ) Treatment of acute ST-segment elevation myocardial infarction (STEMI) managed medically or with subsequent percutaneous coronary intervention (PCI) ( 1.4 ) 1.1 Prophylaxis of Deep Vein […]
Conditions named in the indications of enoxaparin's FDA labels, with every medicine labeled for each:
From other enoxaparin labelsHeart attack and coronary artery disease: … ( 1.2 ) Prophylaxis of ischemic complications of unstable angina and non–Q-wave myocardial infarction (MI) ( 1.3 ) Treatment of acute ST-segment elevation myocardial infarction (STEMI) managed medically or with subsequent percutaneous …
FDA pharmacologic class: Low Molecular Weight Heparin.
Source: FDA drug label (Lovenox), Sanofi-Aventis U.S. LLC, effective May 28, 2026 (SPL set 5017a927-2a24-4f27-89f9-27c805bf7d59), via openFDA; the full label on DailyMed
Is there a generic for enoxaparin (Lovenox)?
The FDA approved the first generic enoxaparin on July 23, 2010. 11 generic applications are approved; 11 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists enoxaparin from 16 labelers under a generic (ANDA) application and from 2 brand labelers. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 1993 earliest approval on file
- 2010 first generic approved
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for enoxaparin (Lovenox)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $6.45 per mL (Enoxaparin 100 mg/mL syringe), down 26% from $8.74 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Enoxaparin 100 mg/mL syringe (generic)
- Lovenox 40 mg/0.4 mL syringe (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Enoxaparin 100 mg/mL syringe | Generic | $6.45 per mL | n/a | -26% |
| Enoxaparin 120 mg/0.8 mL syringe | Generic | $10.42 per mL | n/a | -22% |
| Enoxaparin 150 mg/mL syringe | Generic | $8.90 per mL | n/a | -30% |
| Enoxaparin 30 mg/0.3 mL syringe | Generic | $9.13 per mL | n/a | -6% |
| Enoxaparin 300 mg/3 mL vial | Generic | $9.87 per mL | $29.62 per vial | -12% |
| Enoxaparin 40 mg/0.4 mL syringe | Generic | $7.78 per mL | n/a | -16% |
| Enoxaparin 60 mg/0.6 mL syringe | Generic | $7.45 per mL | n/a | -18% |
| Enoxaparin 80 mg/0.8 mL syringe | Generic | $6.69 per mL | n/a | -25% |
| Lovenox 40 mg/0.4 mL syringe | Brand | $6.78 per mL | $2.71 per single-dose syringe | -0.7% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has enoxaparin been recalled?
The FDA's Enforcement Report lists 6 recalls naming enoxaparin since 2017: 3 Class I (the most serious), 2 Class II, 1 Class III; 3 still ongoing. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| August 5, 2025 | Class II | Cardinal Health Inc. | Correct Labeled Product Mispack: Bags labeled for Enoxaparin Sodium Injection, 80 mg/0.8 mL, contained Enoxaparin Sodium Injection, 30 mg/0.3 mL |
| January 26, 2022 | Class II | CARDINAL HEALTHCARE | CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions. |
| November 17, 2021 | Class I | Sandoz Inc | Temperature Abuse; temperature excursion during shipping |
| February 2, 2021 | Class I | Apotex Corp. | Labeling; Label Mixup; syringe barrels may containing markings for 150 mg/mL (corresponding to 120 mg/0.8mL strength) instead of 100 mg/mL markings … |
| February 2, 2021 | Class I | Apotex Corp. | Labeling; Label Mixup; syringe barrels may contain markings for 100 mg/mL (corresponding to 100 mg/mL strength) instead of 150 mg/mL (corresponding to 120 … |
| December 5, 2017 | Class III | Sanofi-Aventis U.S. LLC | Labeling: Label Error on Declared Strength. A single syringe labeled as 150 mg/1.0 mL was found packaged in a blister labeled as 120 mg/mL |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the enoxaparin label say about other medicines?
The enoxaparin label names 5 other medicines in its interaction, contraindication or warning sections. The labels of 2 other medicines name enoxaparin. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Dipyridamole | drug interactions | These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, salicylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone. |
| Heparin | contraindications | CONTRAINDICATIONS Lovenox is contraindicated in patients with: Active major bleeding History of immune-mediated heparin-induced thrombocytopenia (HIT) within the past 100 days or in the presence of circulating antibodies [see Warnings and Precautions (5.4) ] Known hypersensitivity to enoxaparin sodium (e.g., pruritus … |
| Ketorolac | drug interactions | These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, salicylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone. |
| Tromethamine | drug interactions | These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, salicylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone. |
| Warfarin | warnings and precautions | No patients in the heparin/warfarin group (0 of 4 women) died. |
Other labels that name enoxaparin
Source: FDA drug label (Lovenox), Sanofi-Aventis U.S. LLC, effective May 28, 2026 (SPL set 5017a927-2a24-4f27-89f9-27c805bf7d59), via openFDA; the full label on DailyMed
What do FAERS reports show for enoxaparin?
The FDA Adverse Event Reporting System holds 57,205 reports that list enoxaparin among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 8,879 are coded as a death and 30,776 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as enoxaparin?
3 other medicines are given the same way (subcutaneous) and in the same FDA class as enoxaparin or labeled mainly for the same use (angina), the same class first. Angina lists all 21 medicines labeled for it, by any route. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (subcutaneous) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Dalteparin | Angina, Heart attack and coronary artery disease, Blood clots (DVT and PE) | none listed | n/a | No current entry |
| Evolocumab | Angina, Heart attack and coronary artery disease | none listed | $281.96 per mL 140 mg/mL sureclick | No current entry |
| Alirocumab | Angina, Heart attack and coronary artery disease | none listed | $258.01 per mL 150 mg/mL pen | No current entry |
Every medicine labeled for the same conditions as enoxaparin
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
How does enoxaparin compare with medicines for the same use?
3 side-by-side pages set enoxaparin beside a medicine whose label shares a use: approvals, generics, pharmacy cost, warnings and supply.
What next?
- Alternatives to enoxaparin
- 3 medicines for the same use
- Other low molecular weight heparins
- the pharmacologic class, with prices and generics
- Enoxaparin side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other